Title: Effects of ketamine and esketamine on death, suicidal behaviour, and suicidal ideation in psychiatric disorders: A systematic review and meta-analysis

Running head: Ketamine/esketamine and suicidality

Martin Plöderl [1] (0000-0003-4659-9314), Ruth Cooper [2] (0000-0002-9735-4731), Tom Walker [3] (0009-0004-0886-5428), Vibha Shah [4], Mark Horowitz [5] (0000-0003-1318-2029), Constantin Volkmann [6] (0000-0002-5359-4338), Joanna Moncrieff [7] (0000-0003-1214-6974)

Roles and Affiliations

[1] Clinical Psychologist, Center for Inpatient Psychotherapy and Crisis Intervention, University Clinic for Psychiatry/Psychotherapy/Psychosomatics, Paracelsus Medical University, 5020 Salzburg, Austria. m.ploederl@salk.at

[2] Research Associate, Department of Health Service & Population Research, David Goldberg Centre, 18 De Crespigny Park, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK, SE5 8AF. ruth.1.cooper@kcl.ac.uk

[3] Senior Trainee in Psychiatry, West London NHS Foundation Trust, UB2 4SA London, UK. thomas.walker6@nhs.net

[4] Consultant Psychiatrist, North East London Foundation Trust, Goodmayes Hospital, 157 Barley Lane, Goodmayes, Ilford IG3 8XJ, UK. vibha.shah@nelft.nhs.uk

[5] Clinical Research Fellow in Psychiatry, Research and Development Department, North East London Foundation Trust, Goodmayes Hospital, Ilford IG3 8XJ, UK. mark.horowitz@nelft.nhs.uk

[6] Consultant Psychiatrist, Department of Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany. 8. constantin-volkmann@charite.de

[7] Professor of critical and social psychiatry, Division of Psychiatry, University College London, London WC1E 6BT, and North East London Foundation Trust, Goodmayes Hospital, Essex, IG3 8XJ. j.moncrieff@ucl.ac.uk

Correspondence to: Martin Plöderl, Christian Doppler Clinic, Paracelsus Medical University Salzburg, Ignaz-Harrer-Str. 79, 5020 Salzburg, Austria. m.ploederl@salk.at

ABSTRACT

Obective: Ketamine and esketamine have been claimed to possess anti-suicidal effects and potentially to transform suicide prevention. This study provides an updated overview of evidence from clinical trials to establish whether ketamine or esketamine reduce death, suicides, suicide attempts or suicidal ideation, compared to active or inert placebo among people with psychiatric disorders.

Design: Systematic review and meta-analysis.

Data sources: We searched EMBASE, PubMed and PsycINFO from inception until 02.12.2025.

Eligibility criteria for selecting studies: Eligible for inclusion were randomised controlled trials which compared the effect of ketamine or esketamine with active or inert placebo for the treatment of people with psychiatric disorders. We included trials with concomitant treatments and excluded those where ketamine/esketamine were used as anaesthics.

Data synthesis and study quality: Data were synthesised with meta-analysis, including methods for double-zero events. Risk of bias was assessed using the Cochrane Risk of Bias Tool and quality of the evidence was evaluated using GRADE guidelines.

Results: We included 73 trials with a total of 5671 participants. The majority of trials (56) examined ketamine, 16 esketamine, and 1 arketamine. Twelve of the ketamine trials were cross-over trials and the rest were parallel group trials. A single dose was used in 35 trials. Median length of treatment and follow-up was 45 days. Rates of suicidal behaviour were 1.63% for ketamine/esketamine and 1.72% for placebo, with the 95% credible interval including the null-effect, OR = 0.98 [0.58 to 1.60] (Bayesian Analysis with weak priors). There were 42 (1.43%) suicide attempts, 6 (0.20%) suicides and 9 (0.31%) deaths with ketamine/esketamine compared to 41 (1.64%), 2 (0.08%) and 5 (0.20%) on placebo. Ketamine/esketamine significantly reduced suicide ideation up to 4 weeks (standardized mean differences [SMD] at 12h to 24h of -0.31 [-0.45 to -0.18], I^2 = 26%), but effects were small after 24 hours and dropped to near zero after 4 weeks. Subgroup analysis for suicide ideation revealed that effects of esketamine were close to zero after 24 hours whereas effects for ketamine were small to medium for the first 4 weeks. Effects tended to be larger in trials involving suicidal patients. Repeated dosings were not superior to single doses. Quality assessment revealed unreliable blinding, selective reporting and - especially for suicidal behaviour - imprecision, leading to low or very low certainty ratings for suicidal behaviour and low or moderate certainty ratings for suicide ideation.

Conclusions: There is insufficient evidence for a preventive effect of ketamine/esketamine for suicidal behaviour. The observed immediate but short-term effect on suicide ideation may be overestimated due to unblinding bias. Our review is the most comprehensive on suicidality to date, however, more evidence is needed to draw conclusions on suicidal behaviour.

Other: No specific funding was involved. The protocol was registered with PROSPERO (CRD42023364156).

KEY MESSAGES

What is already known on this topic

- Ketamine and esketamine have been considered to transform suicide prevention with evidence from multiple studies suggesting they may rapidly alleviate depression and suicide ideation.
- There have been numerous calls for studies to investigate if these findings translate to suicidal behaviour. With the many new studies that have emerged only recently, such a review is overdue, together with an update on suicide ideation.

What this study adds

- Despite including studies up to December 2025, evidence on whether ketamine/esketamine can effectively reduce suicidal behaviour remains inconclusive.
- Small to medium effect on suicide ideation within the first 4 weeks (with near zero effects thereafter) were observed for ketamine but for esketamine effects were close to zero already after 24 hours, and unblinding bias is likely involved.
- Repeated doses did not show superiority over single administrations in reducing suicide ideation.

How this study might affect research, practice, or policy

- More studies are needed to judge if ketamine/esketamine can reduce suicidal behaviour, and how unblinding effects might explain the short-term effect on suicide ideation.
- The practice of repeated dosings should be questioned and needs further investigation.

INTRODUCTION

Suicide is a major public health concern across the world. Overall, 1 in 100 people die by suicide and among people aged 15-29 it is the fourth leading cause of death worldwide [1]. In the UK suicide is the most common cause of death among both men and women aged 20 to 34 [2]. Despite a worldwide decline in the rate of suicide since 2000, rates are increasing in the US and some European countries, including the UK [2,3]. A broad range of psychiatric disorders is associated with an increase of suicides and suicide attempts [4].

Ketamine and its S-enantiomer, esketamine, are increasingly used for the treatment of treatment-resistant depression and also investigated for a broader range of mental health problems such as bipolar depression, substance use disorders and anxiety disorders (Table 1). Furthermore, they have been suggested to have the potential to offer rapid relief from suicidal thoughts and to help prevent suicide [5,6] and Esketamine was licensed in the US for people with treatment resistant depression and major depressive disorder with suicidal thoughts or actions [7]. Previous summaries of the literature have claimed promising results for both agents [8–10], suggesting that esketamine is "the only FDA-approved antidepressant that works in hours not weeks – thus potentially transforming treatment of suicidal patients" [8]. There is also some evidence that ketamine reduces suicide ideation independent of depression symptoms [11]. On the other hand, post marketing data suggests that esketamine may be associated with an increase in suicidal ideation and suicides [12] and chronic, recreational ketamine misuse is associated with depression [13–15]. While previous systematic and non-systematic reviews have generally suggested that ketamine and esketamine reduce suicidal ideation and behaviour, at least short-term [16–19], they also highlight methodological limitations of the research and a lack of data on medium or long-term effects [17]. However, these limitations have not been explored in detail, and no existing reviews have considered the outcome of deaths by suicide or suicide attempts, even though reducing suicide is the ultimate aim of this intervention. Moreover, there is the repeated request for using harder outcomes in psychiatric research, such as suicide attempts or suicide, because softer outcomes (reduction in symptom scores) are more prone to bias [20]. Reviews on suicidal behaviour are lacking partly due to the difficulty of conducting meta-analysis of rare events, but statistical methods to manage this situation have been developed recently [21,22]. Furthermore, existing reviews, even those of otherwise good quality, had significant limitations, for example, mixing outcomes at different time-points, or errors in data extraction [18,23,24]. Finally, many studies appeared recently and an update is required.

In the current systematic review and meta-analysis we aimed to answer the following question: does ketamine or esketamine reduce suicidal behaviour (suicides, suicide attempts), deaths of any cause (as additional outcome because suicidal intent is sometimes unknown), and suicidal ideation for people with primary psychiatric disorders? We examined short-term and longer-term outcomes. We also explored methodological limitations of the existing studies.

METHODS

This systematic review and meta-analysis was conducted following guidance from the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines [25]; see Supplement for the PRISMA Checklist.

Eligibility criteria

All randomised controlled trials (RCTs), comparing ketamine or esketamine with inert placebo or active placebo in individuals with a primary diagnosis of any major psychiatric disorder, were eligible for inclusion in this review. Data from the first period of cross-over trials were also included (to protect against the carry-over effect). Trials comparing ketamine or esketamine in combination with an antidepressant, psychotherapy or other intervention were included as long as other interventions were equally available to those in the control group. Studies were excluded if the drugs under investigation were intended as an analgesic and/or anaesthetic agent. In addition, although not specified in the protocol due to being unforeseen at the time, studies were excluded if data on suicidality were not available despite contacting the authors.

Information sources and search strategy

We searched EMBASE, PubMed and PsycINFO from inception until 01.10.2022 using the strategy outlined in Table S1. The search was updated on 09.01.2025 and again on 02.12.2025. We had no language restrictions. We also searched citations of included studies and previous reviews.

Selection process

Two reviewers (initial search and first update TW, MP; second update BAM, MP) independently screened titles and abstracts and subsequently full texts. Discrepancies were resolved by discussion (RC, JM, and MP).

Data collection process

For the initial search and the first search update, authors extracted summary statistics from an assigned portion of selected studies using a standardised form and another author (MP) did an independent extraction. Data from the final search update was extracted by a single author (MP). Uncertainties and discrepancies were resolved by discussion. In cases of missing data or areas of uncertainty, the corresponding author of the paper was contacted with at least one reminder, and we looked up the data on trials registers using the study registration number. Summary statistics from Janssen's esketamine trials were calculated by one author (MP) based on individual patient data accessed via the Yale Open University Data Access (YODA) project. This was validated by comparison with the available summary statistics in the trial publications.

Data items and outcome measures

We extracted the following data: trial design, length of follow-up, participant number and characteristics, intervention, control, and Conflicts of Interest (COIs).

Outcomes consisted of death by any cause, suicides, suicide attempts and suicidal ideation. We extracted outcome data at seven time-points, similar to a previous review [18]: within 4 hours, >4 to ≤12 hours, >12 to ≤24 hours, >24 to ≤72 hours, >72 hours to ≤2 weeks, >2 to ≤4 weeks, and >4 weeks. If there were more than one measure within a specific time frame, we used the one closest to the end of the time frame.

Suicidal behaviour was made up of a composite of suicides and suicide attempts. We checked the trial registers for suicidal behaviour and mortality, and we assumed that no such events occurred when the paper reported that "no serious adverse events occurred" or when tabulated adverse events did not include suicidal behaviour/mortality.

For suicidal ideation, we used results based on assessments with suicide-specific scales such as the Beck Scale for Suicidal Ideation (BSI) or the Columbia Suicide Severity Rating Scale (C-SSRS). If this was not available, we used the suicidal ideation item of a depression rating scale in this hierarchy: the authors designated primary outcome and if this was not specified the Montgomery-Åsberg Depression Rating Scale (MADRS), followed by the Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS), and other scales such as the Quick Inventory of Depressive Symptomatology (QIDS).

When examining the trials, it became clear that there were distinct "treatment phases" and "follow-up" phases, although these were not defined consistently in the original studies. Results from follow-up periods were included as long as randomization was maintained, in order to include data from the same time point in studies with different treatment durations. Data from non-randomized open-label treatment phases were excluded.

Quality assessment

The risk of bias in the included studies was assessed using the Cochrane Risk of Bias tool [26]. This measure rates studies as being at high, low or unclear risk of bias according to various domains. Criteria for the rating of each domain were established by consensus within the research team in accordance with the Cochrane guidelines. Quality assessments for the initial search were carried out by MP, MH, JM, SA, RC, TW, and VS and independently rated by JM or MP. For the two search updates, ratings were done by JM and MP. Discrepancies were resolved by discussion. Quality of the evidence to judge if the confidence that the estimation of the effect is correct was evaluated (JM, MP, RC) using GRADE (Grading of Recommendations, Assessment Development and Evaluation) [27,28] and GRADEPro software.

Synthesis methods

We reported results for suicide attempts, suicides, and mortality according to whether they occurred in the treatment phase, the follow-up phase, and both phases combined, since further information about timing was generally not available. We included studies without any events to avoid biased results, following recent recommendations and different random effects meta-analytic approaches suggested by Xu et al. (2021). These authors also recommended using more than one method to confirm that results are not dependent on a specific method. Therefore, as outlined in our protocol, we used a random effects two-stage exact method [22] and a one-stage Bayesian method as in a previous publication [30] which was based on a binomial-normal hierarchical model. We used weak priors based on empirically derived suggestions, that is, a normal distribution with mean = 0 and variance = 2.82, with a limitation to delta=250, meaning that odds ratios larger than 250 or smaller than 1/250 are considered unlikely, and a half-normal prior for the heterogeneity tau=0.5 [31]. We also used a Bayesian model with a more informative prior (delta = 15, meaning that the odds ratios are in the range of 1/15 to 15). We also ran sensitivity analysis with very weak/informative priors for the treatment effect and for heterogeneity. In addition, we used one-stage frequentist beta-binomial and GLMM methods [32] and the following two stage models: Peto's method, Mantel-Haenszel methods with continuity corrections, and two methods based on risk differences (Mantel-

Haenszel and arcsine transformation methods). All other methods were based on odds-ratios as measures of effect-size. Not specified in the protocol but for ease of interpretation we prioritize the binomial-normal hierarchical Bayesian model with weak priors because this model has been found suitable [31] and considered other models as sensitivity analysis. We considered the results of different models to be consistent if they lead to the same GRADE ratings for imprecision and heterogeneity.

Heterogeneity was assessed with I^2 and τ^2 if the meta-analytic model allowed for this (with R's default parameters). We combined drug-arms for studies with different doses as recommended [33].

For suicide ideation as outcome, we ran random effects meta-analysis using R's "meta" package, with Hedges *g* as measure of effect size, I^2 and τ^2 as measures of heterogeneity (using Sidik & Jonkman's method to estimate heterogeneity). Meta-analyses were based on drug-placebo differences in suicide ideation at specific time-points and not on differences in change from baseline, except for one study where only change-scores were available. Publication bias was explored with Egger's regression test. For the few studies which only reported medians we used the procedure suggested by Wan et al. to calculate means and standard deviations [34]. For one study [35] no information about the standard deviations were available and we imputed these with those from other studies with the same assessment instruments, as recommended [33]. We combined results from multiple arms with different doses following the recommendation by Cochrane [33] or, if possible, by using individual patient data. We planned to conduct various pre-specified subgroup or subset analyses, where sufficient data permitted, namely: inclusion or exclusion of people at significant risk of suicide, different primary psychiatric disorders (including substance misuse), esketamine or ketamine, method of administration (e.g., intravenous, oral), sample size, inert or active placebo, different trial designs (RCT or single blinded trial or open label study) and clinician or self-report measures of suicidal ideation. We also conducted a subgroup analysis of single versus repeated doses which was not included in the protocol but was considered important given the increasing practice of repeated, ongoing dosing. We did not distinguish between the treatment-phase and follow-up phase in the analysis for suicide ideation because this was the only way that longer-term effects from single-administrations could be compared to those of repeated administrations.

We used R 4.3.0 for all analysis [36]. The protocol was developed and registered prior to data extraction (PROSPERO CRD42023364156).

Patient and public involvement

No patient and public involvement happened at the stage of planning the analysis. However, one member of the review-team has experiences of mental health difficulties and treatments. During the data-analysis, a representative of Austria's patient groups who is also a member of the expert panel in Austria's national suicide prevention program SUPRA (Suicide Prevention Austria) was informed about the aims and methods of the review and asked to provide feedback after discussing the study with other representatives of patient groups. This did not result in practical suggestions about the study aims or methodology. Patient representatives felt it was important that the review fulfils quality criteria and will be publicly available. They expressed concerns about the validity of the assessment of suicidality and about potential addiction or dependence problems with longer-term use of ketamine or esketamine. We include these points in the discussion section and intended to publish this review open access.

RESULTS

Study selection and characteristics

The search identified 3118 titles via databases and additional 15 titles via reference checking, of which 264 studies were subjected to full-text screening (Figure 1). A total of 191 studies were excluded following full-text screening (Table S2). A total of 73 studies were identified that met eligibility criteria, including 56 involving ketamine, 16 esketamine, and 1 arketamine. Twelve of the ketamine trials were cross-over trials and the rest were parallel group trials. A single dose was used in 35 trials (33 ketamine trials). In repeated dose trials, doses were administered between weekly and two times daily and treatment lasted between three days and ten weeks. Follow-up lasted between 24 hours to 12 months (median 27 days, interquartile range 7 to 31 days). The trials involved 5671 participants in total. Further characteristics are detailed in Table 1.

Risk of bias and GRADE ratings

Full risk of bias ratings are shown in Figure S2. These revealed that patients and study personnel were rarely likely to be adequately blinded. Only 18 studies tested the integrity of the double blind, of which 13 showed evidence of unblinding among participants and or assessors (Table S3). These included 9 of the 11 studies that employed an active placebo agent such as midazolam or remifentanil, with some of these finding rates of correct guesses by participants and assessors

between 80 and 100% [37,38]. Only three out of these 18 studies were considered adequately blinded, two of which involved administering ketamine along with an anaesthetic [39,40]. Furthermore, we rated 21 (29%) of studies as high risk of bias due to selective reporting of outcomes, and one trial publication did not report suicidality as an outcome despite this being planned (Dwyer. et al. 2021). Overall 61 (84%) trials were rated as being at high risk of bias in some domain. Ratings of the certainty of evidence for estimations of effects for the most important outcomes are summarised in Table 2. For suicide ideation, certainty of the evidence ranged from low to moderate, mainly due to risk of bias due to functional unblinding, and due to imprecision and heterogeneity which varied for different time-points. For suicide attempts and suicides combined, certainty of the evidence was rated as very low due to risk of bias and imprecision, and low for suicide because of imprecision.

Suicidal Behaviour and Deaths

For suicides and suicide attempt combined, and for both the treatment and follow-up phase combined, there were 48 (1.63%) incidents in 2936 patients randomized to ketamine or esketamine compared to 43 (1.72%) incidents in 2504 patients randomized to placebo. The drug-placebo difference included the null effect (OR = 1) and the credible interval was wide, OR = 0.98 [0.58 to 1.60] (Table 3). Results for different priors and other meta-analytic methods lead to comparable findings (Table 3 and supplement). In the treatment-period, there were 20 (0.68%) incidents with ketamine/esketamine and 15 (0.60%) with placebo, and for the follow-up period there were 28 (1.96%) and 28 (2.21%) incidents, respectively. None of the meta-analytic results were statistically significant (Table 3, forest-plots with results for individual studies in Supplement). The number of deaths of any cause in combined treatment and follow-up phases was 9 (0.31%) in ketamine or esketamine and 5 (0.20%) in the placebo groups and the credible interval in the meta-analysis overlapped with the null-effect, OR = 1.41 [0.57 to 3.65] (Table S13). For suicides, there were 6 (0.20%) incidences with ketamine or esketamine compared to 2 with placebo (0.08%), OR = 1.58 [0.55 to 4.96] (Table S10). For suicide attempts, there were 42 (1.43%) incidences with ketamine or esketamine, compared to 41 (1.64%) with placebo and again the difference overlapped with the null-effect, OR = 0.87 [0.50 to 1.45] (Table S7). Results were comparable with other meta-analytic models and for different treatment phases (Tables S4-S15). None of the drug-placebo differences for deaths, suicides, and suicide attempts were statistically significant. There was no indication of reporting bias in any of the analysis for suicidal behaviour and deaths.

Suicide Ideation

Suicidal ideation was statistically significantly reduced among people allocated to ketamine/esketamine compared to placebo, with a small to medium effect size up to 24 hours after randomisation (SMD -0.31 [-0.45 to -0.18], $p < 0.001$ for > 12h up to 24h). At subsequent follow-ups differences were small (point sizes about SMD 0.20) and after 4 weeks follow-up they were close to zero and not statistically significant (Table 4, Figure 2). An end of treatment phase analysis (combining results from studies of all durations) showed a significant effect, SMD = -0.25 [-0.35 to -0.15]. Heterogeneity was only statistically significant for results in the first 4 hours and for >24h up to 72h. There was no indication of publication bias in any of the analyses for suicidal ideation.

Subgroup analysis

Deaths, suicides and suicide attempts were too rare to do subgroup analyses. For suicidal ideation, subgroup analysis for different types of drugs showed that the effects of ketamine were consistently larger than esketamine up to 4 weeks, with some differences being statistically significant, too (Table 5). Esketamine's efficacy was close to zero after 24 hours, whereas the efficacy of ketamine remained significant up to 4 weeks and end of treatment. The significant heterogeneity at 24h up to 72h for drugs combined disappeared within individual drugs (Ketamine, SMD -0.37 [-0.57 to -0.18], Esketamine SMD -0.03 [-0.13 - 0.08]). Efficacy was numerically larger in trials where suicidality was an inclusion criterion (vs. suicidality as exclusion criteria or unspecified) in the first two weeks and end of treatment with some differences also being statistically significant. Trials with active placebos (defined as an active drug) had larger effects than trials with inert placebos (including those with a bittering agent) with significant differences as several time-points. There were no significant differences between trials where suicide ideation was assessed by a clinician compared with by patients. There was insufficient data for comparing different diagnoses (most studies involved MDD), trial design, or low risk of bias (or post-hoc, exploratory subgroup analysis for age-groups, doses, etc.). In the explorative subgroup analysis, repeated administrations were not statistically significantly superior to a single dose at any time point (we ran analysis after 72h since repeated dosing usually starts after this time point).

DISCUSSION

The evidence that ketamine or esketamine prevent suicidal behaviour or mortality is inconclusive. Numerically, there were fewer suicide attempts and more suicides and deaths in the drug arms than in the placebo arms, but there is much uncertainty in the estimations of differences. Medium-sized

protective effects on suicide ideation were only observed up to three days, and these were generally smaller for esketamine than ketamine. Repeated dosings were not superior to single doses.

In general, drawing conclusions is hampered by the lack of long-term data, insufficient statistical power, and selective reporting. Another problem is the acute psychoactive effects of ketamine/esketamine. These may influence suicidal ideation and mood in their own right, and may also undermine the double blind design. This was confirmed by the few trials which tested blinding and found that it was mostly not successful, even for active placebos [42,43]. In two trials in which ketamine was given during an anaesthetic procedure and blinding was successful, the drug-placebo differences were close to zero (see subgroup analysis in Supplement). In one of these, people who guessed they had had ketamine showed substantially lower symptoms at follow-up than people who guessed they had had placebo (p=0.001), despite there being no effect of the actual substance [40]. The assumption that functional unblinding leads to an overestimation of efficacy is also supported by a lack of drug-placebo differences for depressive symptoms in trials where functional unblinding is likely reduced because ketamine/esketamine was given in addition to anaesthics in electroconvulsive therapy [39,44–47], or as an anaesthic agent compared to another anaesthic [48,49]. In addition, selection biases and expectancy effects may interact with functional unblinding. In a recent trial, for example, no effect on depression was found for a course of up to 8 ketamine infusions and the authors argued that this may be explained by the enrollment of patients from an academic center instead of self-selected patients [50].

Furthermore, it remains unknown if the evidence base for ketamine/esketamine is affected by problems seen in antidepressant research where suicidal behaviour was sometimes reclassified as emotional worsening or “drop-out” [51,52]. In addition, it is often not clear if suicidal behaviour was assessed by blinded raters, which is known to result in lower efficacy compared to non-blinded raters [53]. Whereas assessment of suicide ideation was often part of a separate and systematic assessment process, suicidal behaviour was often only identified during the assessment of spontaneously reported adverse events. Consequently, our risk of bias assessment provides a conservative estimation of the likely biases due to rater blinding.

Esketamine is approved by the FDA and increasingly used but appears less effective than ketamine. This was also reported in other reviews with depression symptoms as an outcome [17,23,54,55] and may reflect greater amplified placebo effects of ketamine, which is usually administered intravenously. More head-to-head comparisons are needed for clarification.

A challenge to the clinical practice of repeated dosings for maintaining efficacy [23] is our explorative finding that this is not superior to single doses. This has not been systematically explored in placebo controlled trials, to our knowledge, but is in line with a recent finding of controlled and uncontrolled trials based on pre-post differences [56]. The diminishing effect could be explained by decreasing expectancy effects over time or tolerance effects. This result challenges claims that ketamine or esketamine work by stimulating neurogeneration or other processes that evolve over time.

Although numbers of suicides and deaths of any cause were small, the fact that they were higher in the ketamine/esketamine arms than in the placebo arms may represent a signal of concern, given that post-marketing surveillance data on esketamine suggests it may increase the incidence of suicidal ideation and behaviour [12]. Of note, two additional suicides and one other death occurred in drug-arms of enrichment or open label phases of studies that were excluded from our analysis [57,58]. However, suicide attempts were numerically lower in the drug arms. Concerns about potential addiction problems from longer-term use were also pointed out by our patient representatives and are well known [59,60].

Strengths of this review include the inclusion of suicidal behaviour and mortality and statistical methods to handle these rare events, thus avoiding biases resulting from excluding trials with zero events. Previous reviews were either outdated or did not report on suicidal behaviour as outcome, especially not on suicides and deaths of any cause [16–18]. Furthermore, in contrast to some previous reviews, results for suicide ideation were aggregated for different time points and the review is up to date by including studies up to December 2025. The larger number of included studies replicated the findings of a short-term effect on suicide ideation and the weaker effect for esketamine compared to ketamines [17,19,23,55], but is more precise. Limitations include potential biases resulting from our assumption that no suicidal behaviour occurred when none were mentioned in the reported adverse events. Some authors did not respond to data requests and this may introduce bias if non-response is systematically related to published outcomes. Additional limitations also affecting other reviews include the use of means and standard deviations when suicide ideation has a skewed distribution or when suicide ideation was measured on a Likert-scale with few response options, and that studies did not report results separately by sex/gender, and that follow-up time-frames substantially varied (and that we had no further information about the exact timing of events to be able to restrict time-frames).

In conclusion, there is insufficient data to ascertain whether ketamine or esketamine reduce suicide and suicide attempts. Short-term effects for ketamine on suicide ideation are detected, but these are not sustained and may be the product of acute psychoactive effects or unblinding, contributing to the low quality of efficacy estimations.

ACKNOWLEDGEMENTS

We thank the authors who responded to our requests for data. We also thank Janssen and Yale for making patient-level data available via the YODA platform (YODA statement: "This study, carried out under YODA Project [2024-0612], used data obtained from the Yale University Open Data Access Project, which has an agreement with JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. The interpretation and reporting of research using this data are solely the responsibility of the authors and does not necessarily represent the official views of the Yale University Open Data Access Project or JANSSEN RESEARCH & DEVELOPMENT, L.L.C.."). We thank Silvi Mühringer, patient representative of SUPRA Austria for discussions and suggestions for our study. We thank Simone Amendola for assistance in designing the study and data-extraction and Blanca Acimas Müller for independent screening of the search update.

Research ethics and consent

This is a systematic review of already published studies.

Contributor and guarantor information

Protocol development: MP, RC, TW, MH, CV, JM; literature search: TC, VS, MP, JM; data extraction, data management, data-cleaning: MP, RC, TW, VS, MH, CV, JM, statistical analysis: MP, drafting: MP, RC, JM; reviewing and revising: MP, RC, TW, VS, MH, CV, JM. Responsible for overall content and guarantor: MP and JM. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Copyright/licence for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the

Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Competing interests

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: CV, MP, RC, TW, VS no support from any commercial organisation for the submitted work and have no other conflicts of interest to declare; JM has received royalties for books about psychiatric drugs; MH received support from a clinical research fellowship at NELFT (NHS), royalties from the Maudsley Deprescribing Guidelines, and is a co-founder of Outro Health, a digital clinic in the US where he receives consulting fees.

Data sharing

The data and statistical code are available on the OSF https://osf.io/xzj7k/

Caption to Figure 1

Figure 1. PRISMA flowchart.

Caption to Figure 2

Figure 2. Meta-analytic results for effects of ketamine and esketamine on suicide ideation at different time-points. The y-axis refers to the standardized mean-difference. Negative values correspond to increased reduction in suicide ideation in the drug arms compared to the placebo arms. The horizontal dashed lines are two thresholds for clinical significance at SMD = -0.3 and SMD = -0.5.

Table 1. Study characteristics

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
Abbar 2022 [54], France, NCT02299440	156 (73/83)	Adults with Bipolar disorder, depression, other disorders; current suicidal ideation	Double blind RCT	**TR:** 2 days **TR+FU**: 6 weeks **TR+FU for analysis**: 6 weeks	IV Ketamine (0.5mg/kg), 2 doses given at baseline and 24 hours.	Placebo: saline	BSS – clinician	Yes, directly Timing of suicide attempts clarified with author	Yes
Abdallah 2022 [61], USA, NCT02655692	158 (104/54)	Adult (18 to 70) veterans; PTSD; no suicidality meriting crisis intervention	Double blind RCT	**TR**: 4 weeks **TR+FU**: 8 weeks **TR+FU for analysis**: only 4-week TR because TR-nonresponders were offered open label ketamine in FU	IV Ketamine (0.2 and 0.5mg/kg), twice weekly, 4 weeks	Placebo: saline	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported on trial register	Yes
Ahmed 2023 [62](30) Egypt NCT04101474	36 (18/18)	Adults (18 to 65 years); MDD; current suicidal risk	Double blind RCT	**TR**: 2 weeks **TR+FU**: 3 weeks **TR+FU for analysis**: 3 weeks	IV Ketamine (0.5mg/kg), 2 doses over 2 weeks	Placebo: saline	SPS, using the post-dose assessments	Yes, directly Not reported but author confirmed that no events occurred	No
Anderson 2017, [39,63] UK, ISRCTN 14689382	79 (40/39)	Adults with Uni- or bipolar depression; suicidality not specified in eligibility criteria	Double blind RCT	**TR**: varied – max 10 weeks. **TR+FU**: max. 26 weeks. **TR+FU for analysis**: max. 26 weeks	IV Ketamine (0.5mg/kg) as an adjunct to ECT anaesthetic + ECT course. Twice weekly, average 11 ECT treatments (in both arms)	Placebo: saline + ECT course	MADRS-SI, data from Witt et al. 2019 who requested data from authors	Yes, directly Timing of suicide attempts assumed to coincide with reported detainments in EUDRA information	No
Barzkar 2025 [64], Iran, IRCT20220118053756N1	36 (18/18)	Adults (18 to 65 years); MDD with current suicide ideation	Double blind RCT	**TR**: 24 hours (single dose) **TR+FU:** 24 hours (no longer FU) **TR+FU for analysis**: 24h	IV Ketamine (0.5mg/kg), single dose	Active control: midazolam (0.02mg/kg)	BSS - clinician	Yes, directly Paper reports that no serious AE occurred.	No
Burger 2016 [35], USA, none reported	10 (3/7)	Adults (18 to 65 years, on active military duty) with depression and suicidality; current suicidal ideation	Double blind RCT	**TR**: 24 hours (single dose) **TR+FU:** max. 3 weeks (max. 1 week inpatient treatment with 2 weeks follow up **TR+FU for analysis**: max 3 weeks	IV Ketamine (0.2 mg/kg), 1 dose	Placebo: saline	BSS – patient, M's from figure, SD's imputed with other studies using patient-BSS	Yes, indirectly No events in AE reported in paper	Not reported

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
Canuso 2018, [65], USA, NCT02133001	68 (36/32)	Adults (19 to 64 years) with MDD; current suicidal ideation	Double blind RCT	**TR** : 25 days **TR+FU**: 81 days **TR+FU for analysis:** 81 days	Intranasal Esketamine, 84mg (max total dose), twice weekly for 4 weeks	Placebo with bittering agent[a]	SIBAT Module 8, data via YODA	Yes, directly	Yes
Chen 2023, [66], USA + China, NCT03434041	252 (126/126)	Adults (18 to 64 years) with MDD, no current suicide ideation with intent	Double blind RCT	**TR**: 4 weeks **TR+FU**: 12 weeks **TR+FU for analysis**: only 4-week TR because in some patients moved to other trial afterwards	Intranasal Esketamine, 56mg up to 84mg, twice weekly for 4 weeks	Placebo	C-SSRS, data via YODA	Yes, directly	Yes
Colla 2024 [67], Switzerland SNCTP Nr. 000002938	30 (20/10)	Adults (18 to 70 years); moderate to severe depression; exclude suicidality	Double blind RCT	**TR:** 2 weeks **TR+FU**: 2 weeks (no FU) **TR+FU for analysis**: 2 weeks	Ketamine, 2 dose groups: 160mg or 240mg per day for 14 days	Placebo	SSF	Yes, indirectly No events in AE reported in paper	Yes
Dakwar 2019 [68], USA, NCT01535937	55 (27/28)	Adults under age 70; SUD (Cocaine); nothing mentioned regarding suicidality	Double blind RCT	**TR:** 24h (single dose) plus 5 week mindfulness based therapy **TR+FU**: 31 weeks **TR+FU for analysis**: 31 weeks	Intravenous Ketamine 0.5mg/kg, 1 dose + mindfulness behavioural modification	Active control: Midazolam, 0.025mg/kg + mindfulness behavioural modification	Not assessed	Yes, indirectly No events in AE reported in the trial register	Yes
Dakwar 2020 [69], USA, NCT02539511	40 (17/23)	Adults under age 70; SUD (Alcohol); excluded when current suicide risk or past year suicide attempt (according to protocol)	Double blind RCT	**TR**: 24h (single dose) in second week of 5 week psychological treatment **TR+FU**: 31 weeks **TR+FU for analysis**: 30 weeks	Intravenous Ketamine 0.71mg/kg, 1 dose + motivational enhancement therapy	Active control: Midazolam, 0.025mg/kg + motivational enhancement therapy	Not assessed	Yes, indirectly No events in AE reported in the trial register	Yes
Daly 2018 [70] (36) USA, Belgium NCT01998958	Panel A: 67 (34/33) (phase 1) Panel B: 41 (20/21) (phase 1)	Adults (20 to 64 years) with MDD and TRD; excluded current suicidal ideation	Double blind, doubly randomised, delayed start RCT Phase 1: participants randomised.	**TR**: 7 days (phase 1), 7 days (phase 2). Open label phase: 59 days **TR+FU**: 130 days **TR+FU for analysis:** 7 days (phase 1) – pre-crossover and pre-open label phase (randomization only upheld in phase 1)	Panel A: Intranasal Esketamine, 3 dose groups: 28, 56, or 84mg twice weekly for each of the 2 weeks (double blind phase) Panel B: Intranasal	Placebo with bittering agent[a]	C-SSRS, data via YODA	Yes, directly	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
			Phase 2: placebo group with moderate/severe symptoms re-randomised to intervention.		Esketamine, 2 dose groups: 14 or 56mg twice weekly				
Domany 2019 [71], Israel NCT02037503	41 (22/19)	Adults (18 to 75 years); MDD; suicidality: not reported	Double blind RCT	**TR**: 21 days **TR+FU**: 28 days **TR+FU for analysis**: 28 days	Oral Ketamine (1mg/kg) three times a week	Placebo: saline	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in publication	Not reported
Domany 2020 [72], USA, NCT01887990	18 (9/9)	Adults (18 to 65) with MDD, bipolar depression, depression, dysthymia; current suicidal ideation	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 14 days **TR+FU for analysis**: 14 days	IV Ketamine (0.2mg/kg), 1 dose	Placebo: saline	BSS – patient, from figure	Yes, indirectly No events in AE reported in trial register	No
Domany 2021 [73], USA NCT02183272	30 (15/15)	Adults (18 to 65 years); eligible participants – required hospitalisation due to suicidal risk	Double blind RCT	**TR**: 24 hours (single dose) **TR+FU**: 28 days **TR+FU for analysis**: 28 days	IN Ketamine, 40mg, single dose	Placebo: saline	BSS – patient, from figure	No Only specific AEs reported, no information on the trial register, no response from author	Not reported
Duek 2023 [74] USA NCT02727998	28 (14/14)	Adults; PTSD; current suicide risk excluded (protocol: ongoing serious suicidal risk as assessed by evaluating investigator or by scoring 5 or more on item-10 of the MADRS)	Double blind RCT	**Length of treatment phase:** 24 hours (single dose) **End of treatment FU**: 90 days **Total trial duration**: 90 days **FU used in analysis:** 90 days	IV Ketamine (0.5mg/kg) Single dose + Psychoptherapy (Retrieve and reprocess exposure therapy)	Active control: Midazolam + Psychopthera py (Retrieve and reprocess exposure therapy)	BDI-SI, raw-data available online	Yes, indirectly No events in AE reported in trial register	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
Dwyer 2021 [41] USA NCT02579928	17 (6/11)	Adolescents (13 to 17 years); MDD; excluded active suicidal ideation	Double blind crossover RCT	**TR:** 24 hours (single dose), cross-over 2 weeks later **TR+FU**: 28 days (both cross-over phases) **TR+FU for analysis**: 14 days	IV Ketamine (0.5 mg/kg) single dose	Active control: Midazolam	BSS, C-SSRS, and other measures data not available	Yes, indirectly No events in AE reported in trial register	Yes
Fava 2020 [38] USA, NCT01920555	99 (80/19)	Adults with MDD and TRD (18 to 70 years); suicidality not specified in eligibility criteria	Double blind RCT	**TR**: 24 hours (single dose) **TR+FU**: 30 days **TR+FU for analysis:** 30 days	IV Ketamine, 1 dose, 3 dose groups: 0.1, 0.2, 0.5, 1.0 mg/kg	Active control: Midazolam	MADRS-SI, data unavailable	Yes, directly	Yes
Feder 2014 [75], USA, NCT00749203	41 (22/19)	Adults (18 to 55 years) with chronic PTSD, excluded when active suicidality	Double blind crossover RCT	**TR**: 24 hours (single dose), cross-over 2 weeks later **TR+FU:** 4 weeks (both cross-over phases) **TR+FU for analysis**: 2 weeks	IV Ketamine (0.5 mg/kg) single dose	Active control: Midazolam (0.045mg/kg)	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in trial register	Yes
Feder 2021 [76], USA, NCT02397889	51 (15/15)	Adults (18 to 70 years) with chronic PTSD, excluded when active suicidal ideation	Double blind RCT	**TR**: 2 weeks **TR+FU**: max 7.5 months **TR+FU for analysis**: only 2-week TR because only responders were followed up	IV Ketamine (0.5 mg/kg) thrice weekly for two weeks	Active control: Midazolam (0.045mg/kg)	C-SSRS, data unavailable	Yes, directly Paper reports that there was no suicidal behaviour, and no deaths in AE in trial register	Yes
Fedgchin 2019 [77], America, Europe NCT02417064	346 (233/113)	Adults (18 to 64 years) with MDD and TRD; excluded suicidality (some ideation possible)	Double blind RCT	**TR:** 4 weeks **TR+FU:** 28 weeks **TR+FU for analysis:** only 4-week TR because responders could enter other trial	Intranasal Esketamine 56, 84mg twice weekly for 4 weeks	Placebo with bittering agent[a]	C-SSRS, data via YODA	Yes, directly	Yes
Fineberg 2023 [42], USA NCT03395314	22 (10/12)	Borderline Personality Disorder; excluded current acute suicide risk	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 28 days **TR+FU for analysis:** 28 days	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	BSS – clinician, data from figure in appendix	Yes, indirectly No events in AE reported in trial register	Yes
Fu 2020 [38], USA, Europe, Asia, South Africa, NCT03039192	226 (114/112)	Adults (18 to 64 years), MDD; current suicidal ideation	Double blind RCT	**TR:** 25 days **TR+FU:** 90 days **TR+FU for analysis:** 90 days	Intranasal Esketamine, 84mg, twice weekly for 4 weeks	Placebo with bittering agent[a]	CGI-SS-r, data via YODA	Yes, directly	Yes
Gallagher [78], Ireland, NCT	25 (13/12)	Adults (18 years or older), MDD;	Double blind RCT	**TR:** 4 weeks **TR:** 11 weeks	IV Ketamine (0.5mg/kg), weekly for	Active control:	HDRS-SI, data from author	Yes, directly No event in AE reported	No

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
NCT03256162		excluded when active suicidal ideation		**TR+FU for analysis:** 15 weeks	4 weeks	Midazolam (0.045mg/kg)		in paper and trial register	
George 2017 [79], Australia, NCT01441505	16 (12/4)	Older adults (≤60 years), MDD, Bipolar disorder; high suicide risk excluded.	Crossover RCT	**TR:** 5 weeks with repeated cross-over. Remitters could exit the treatment phase after 1 week. Open label phase: 8 weeks **TR+FU:** 65 weeks **TR+FU in analysis:** only first week (before first cross-over)	Subcutaneous Ketamine, weekly over 5 weeks: 0.1, 0.2, 0.3, 0.4, 0.5 mg/kg (blinded treatment phase)	Active control: Midazolam, single dose randomly inserted in first 3 treatment sessions	MADRS-SI, data from Witt et al. 2019 who obtained data from author	Yes, indirectly No events in AE reported in publication	Yes
Grabski 2022 [80], UK, NCT02649231	96 (48/48)	Adults (18 to 65 years); Alcohol use Disorder; excluded suicidal ideation	Double blind RCT	**TR:** 1 week-3 weeks **TR+FU:** 6 months from first treatment **TR+FU for analysis**: 26-28 weeks	2 groups: IV Ketamine (0.8 mg/kg) 3 times over max 3 weeks + psychological therapy (group 1) or + alcohol education (group 2)	Placebo: saline + psychological therapy (group 1) or + alcohol education (group 2)	BDI-SI, data provided by author	Yes, indirectly No events in AE reported in trial register	Yes
Glue 2024b [43] New Zealand ACTRN12619000311156	29 (17/8 completers)	Adults (18 to 50 years); MDD; excluded significant suicidal ideation	Double blind crossover RCT	**TR:** 24 hours (single dose), first crossover after 1 week **TR+FU**: 3 weeks **TR+FU for analysis**: 1 week	IV Ketamine (2 groups: 0.5 or 1 mg/kg), single doses	Active control: fentanyl	MADRS-SI, data provided by author	Yes, indirectly No events in AE reported in publication	Yes
Grunebaum 2017 [81], USA, none reported	16 (7/9)	Adults (18 to 65 years), Bipolar Disorder and major depressive episode; current suicidal ideation	Double blind RCT with open label phase	**TR:** 24 hours (single dose) **TR+FU:** 6 weeks **TR+FU used for analysis: only** 24 hours TR because open label treatment with ketamine (single dose) for non-responders in the control group after 24 hours	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	BSS – clinician, data from Witt et al. 2019 but, in contrast to Witt, only up to 24h	Yes, directly	Yes
Grunebaum 2018 [82], USA, NCT01700829	82 (41/41)	Adults (18-65 years); MDD; current suicidal	Double blind RCT with open label	**TR:** 24 hours (single dose) **TR+FU:** 6 weeks **TR+FU used for analysis:** only 24	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	BSS – clinician, data from Witt et al. 2019 but, in contrast to	Yes, directly Reported overdoses in Table S6 were suicide	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
		ideation	phase	hours TR because open label treatment with ketamine for non-remitters afterwards			Witt, only up to 24h	attempts, as confirmed by author	
Hong 2025 [83] , China, ChiCTR2300068591	236 (118/118)	Adults (18-65 years); MDD and smoking; no suicide attempt in past 6 months	Double blind RCT	**TR:** 8 weeks **TR+FU:** 6 months **TR+FU used for analysis:** 8 months	Intranasal Esketamin (0.5mg/kg)	Placebo: sSaline with bittering agent	Suicide item from HDRS, but data not available	Yes, directly Reported in adverse events	No
Hu 2016 [84], China, none reported	30 (15/15)	Adults (18-60 years); MDD; excluded if had suicide attempt during current episode	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 4 weeks **TR+FU used for analysis**: 4 weeks	IV ketamine (0.5mg/kg) single dose + escitalopram	Saline + escitalopram	QIDS-SR	No Only specific AEs reported, no information on the trial register, no response from author	Yes
Ionescu 2019 [85], USA, NCT01582945	26 (13/13)	Adults (18 to 65 years); MDD; current suicidal ideation	Double blind RCT	**TR:** 3 weeks **TR+FU:** 15 weeks **TR+FU for analysis:** 15 weeks	IV ketamine (0.5mg/kg) 6 times to 2 infusions a week, for 3 weeks	Saline	C-SSRS, n's assuming no drop to out, exact time of infusion not given thus results for 72h unavailable	No Cannot be clarified with information in publication or trial register, author did not respond	Yes
Ionescu 2020 [86], Argentina, various European countries, Turkey, USA. NCT03097133	230 (115/115)	Adults (18 to 64 years); MDD; current suicidal ideation	Double blind RCT	**TR:** 25 days **TR+FU:** 90 days **TR+FU used for analysis**: 90 days	Intranasal esketamine 84mg twice weekly for 4 weeks	Placebo with bittering agent[a]	CGI-SS-r, data via YODA	Yes, directly	Yes
Janik 2025 [87], USA , NCT04599855	476 (226/250)	Adults (18 years or older); MDD; excluded when current or recent suicide ideation or behaviour	Double blind RCT	**TR:** 4 weeks **TR+FU**: up to 4 months plus 1 week **TR+FU for analysis:** only 4 week TR phase because afterwards non-randomized open label treatment	Intranasal esketamine, 56mg and 84mg, twice weekly	Placebo	C-SSRS, data via YODA	Yes, directly (YODA)	Yes
Jelovac 2025 [50], Ireland, NCT04939649	65 (32/33)	Adults (18 years or older); MDD; no active suicidality	Double blind RCT	**TR:** ? (1 to 4 weeks) **TR+FU**: ? (1 to 4 weeks) + 24 weeks **TR+FU for analysis:** ? (1 to 4 weeks) +24w	IV Ketamine (0.5mg/kg) up to 8 doses during inpatients stay, twice weekly	Active control: Midazolam (0.045mg/kg)	MADRS-SI Data not available	Yes, directly	No

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
Jones 2024 [88] USA NCT03539887	29 (18/11)	Adults (21 to 60 years); MDD, bipolar depression, with/without comorbid alcohol use disorder; current suicidal ideation	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 48 hours **TR+FU for analysis:** 48 hours	Intranasal Ketamine, 50mg, single dose	Placebo: saline	BSS – clinician, data from figure	Yes, indirectly No events in AE reported in trial register	Yes
Kosik-Gonzales 2025 [89], USA, Spain, France, Brazil, Italy, Hungary, Poland NCT03185819	147 (84/63)	Adolescents (12 to <18 years); MDD, current suicidal ideation with intent	Double blind RCT	**TR:** 25 days **TR+FU**: 200 days **TR+FU for analysis:** 200 days	Intranasal ketamine, (28, 56, 84mg), twice weekly for 4 weeks plus oral placebo	Intranasal placebo plus oral midazolam 0.125 mg/kg	CGI-SS-r, data from figures (not available via YODA)	Yes, directly	Yes
Lapidus 2014 [90], USA, NCT01304147	20 (10/10)	Adults (21 to 65 years), MDD chronic or recurrent without psychotic features, excluded when high risk of suicide	Double blind crossover RCT	**TR:** 24 hours (single dose), crossover after one week **TR+FU**: 14 days **TR+FU for analysis:** 7 days	Intranasal Ketamine, 50mg, single dose	Placebo: saline	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in trial register	Yes
Leal 2023 [91] Brazil UMIN000038347	10 (5/5)	Adults (18 to 65 years); MDD; suicidality not specified in eligibility criteria.	Double blind RCT with crossover	**TR:** 24 hours (single dose), crossover after one week **TR+FU**: 2 weeks **TR+FU for analysis:** 1 week	IV Arketamine (0.5 mg/kg) single dose	Placebo: saline	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in publication	Yes
Lii 2023 [40], USA, NCT03861988	40 (20/20)	Adults (18 to 80 years, mean age 51 years), MDD, excluded when "subject is at significant risk for suicidal behaviour during participation in the study"	Triple blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 14 days **TR+FU for analysis:** 14 days	IV Ketamine (0.5 mg/kg), single dose	Placebo: saline	MADRS-SI, data from author	Yes, indirectly No suicidal behaviour but one death reported in trial register	Yes
Lijffijt 2022 [92] USA	33 (20/13)	Adults (>55 years); MDD; excluded	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 7 days, 28 days for	IV Ketamine (3 groups: 0.1, 0.25, 0.5 mg/kg),	Active control:	C-SSRS, data unavailable	Yes, directly	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
NCT02556606		when serious or imminent suicide risk according to publication on study methods		responders at day 7 **TR+FU for analysis:** 7 days	single dose	Midazolam			
Loo 2016 [93], Australia, none reported	15 (all participants took intervention /control dose)	Adults (18+ years); MDD; clinician interview; not specified	Double blind RCT with crossover	**TR:** 5 weeks, crossovers at least one week separated **TR+FU:** max. 31 weeks **TR+FU for analysis**: 1-2 week (afterwards those on midazolam may have been randomized to ketamine)	Ketamine (0.1, 0.2, 0.3, 0.4, 0.5 mg/kg) 3 routes of administration: IV, intramuscular, subcutaneous. Patients assigned to receive 1 route	Active control: Midazolam, single dose randomly inserted into the first 3 treatment sessions	MADRS-SI, data from Witt et al. 2019 who obtained data from authors	Yes, directly Confirmed by author that no suicidal behaviour and deaths occurred	Yes
Loo 2023 [94], Australia, New Zealand ACTRN12616001096448	181 (89/92)	Adults (≥ 18 years); MDD; suicidality not specified in eligibility criteria.	Double blind RCT	**TR:** 4 weeks **TR+FU**: max. 26 weeks (for those who entered open label phase) **TR+FU for analysis:** only 4-week TR	Ketamine, subcutaneously, First cohort with fixed dose: 0.5mg/kg. Second cohort flexible dose: 0.5- 0.9 mg/kg, twice weekly for 4 weeks	Active control: Midazolam	MADRS-SI, data yet unavailable	Yes, directly timing of suicide attempts clarified with author (both were in the 4-week treatment phase)	Yes
Milak 2020 [95], USA, NCT01558063	43 (38/5)	Adults (18 to 59 years), MDD; excluded actively suicidal patients.	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 24 hours **TR+FU for analysis:** 24 hours	Intravenous Ketamine (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg) single dose	Placebo	HDRS-SI, data unavailable	Yes, directly No events in AE reported in trial register, confirmed by author	No
Murrough 2013, [96], USA, NCT00768430	73 (48/25)	Adults (21 to 80 years); MDD; excluded actively suicidal patients.	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 7 days (non-responders), 4 weeks or until relapse (responders) **TR+FU for analysis:** 7 days **Follow up used in analysis:** 7 days	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	MADRS-SI, data from Witt et al. 2019 who obtained data from author	Yes, directly	Yes
Murrough 2015, [97], USA, NCT01507181	24 (12/12)	Adults (18 to 80 years); suicidal ideation (>4 on MADRS item 10), had a range of mood and anxiety	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 7 days and 5-week safety assessment **TR+FU for analysis:** 7 days (no data beyond this available)	Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	BSS – patient, data from Witt et al. 2019 who obtained data from author (erroneously reported as MADRS)	Yes, indirectly No events in AE reported in trial register	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
		disorders; current suicidal ideation							
Ochs-Ross 2020 [98], USA, Europe, Brazil, South Africa, NCT02422186	138 (72/66)	Older adults (≥65 years); MDD; excluded suicidal ideation with intent to act	Double blind RCT with open label phase	**TR:** 4 weeks **TR+FU:** 6 weeks **TR+FU for analysis:** only 4-week TR because afterwards patients could participate in an open label study	Intranasal Esketamine (28, 56, or 84 mg) twice weekly for 4 weeks.	Placebo with bittering agent	C-SSRS, data via YODA	Yes, directly	Yes
Ohtani 2024 [99], Japan jRCTs031210124	34 (17/17)	Adults (20 to 59 years); MDD; suicidality not specified in eligibility criteria.	Double blind RCT	**TR:** 14 days **TR+FU**: max. 28 days (max. 14 days after the last dose) **FU used for analysis:** max. 28 days	IV Ketamine (0.5 mg/kg), twice weekly for 2 weeks	Placebo: saline	MADRS-SI, data provided by author	Yes, directly No events in AE reported in trial register, confirmed by author	Yes
Pattanaseri 2024 [100], Thailand NCT05026203	21 (11/10)	Adults (18 to 64 years); MDD; suicidality not specified in eligibility criteria.	Double blind RCT	**TR:** 3 days **TR+FU**: 31 days **TR+FU for analysis:** 31 days	IV Ketamine (0.5 mg/kg), 3 doses over 3 days	Active control: Midazolam	MADRS-SI, data provided by author	Yes, indirectly No events in AE reported in trial register	No
Phillips 2019 [101], Canada, NCT01945047	43 (22/21)	Adults (18 to 65) with treatment resistant depression, suicidality not specified in eligibility criteria	Double blind crossover RCT	**TR:** 24 hours (single dose), crossover after min. 7 days **TR+FU:** min. 14 days **TR+FU for analysis:** 7 days Trial had two more open label phases which cannot be used	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam 30 microgram/kg	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in publication	Yes
Popova 2019 [102], USA, Europe, NCT02418585	227 (114/109)	Adults (18 to 64 years); Depression or MDD; excluded suicidal ideation with intent to act or suicidal behaviour	Double blind RCT	**TR:** 4 weeks **TR+FU:** max. 28 weeks **TR+FU for analysis**: only 4-week TR because responders entered other trial	Intranasal esketamine (56 or 84mg) twice weekly for 4 weeks	Placebo with bittering agent[a]	C-SSRS, data via YODA	Yes, directly	Yes
Price 2022 [103], USA NCT03237286	154 (103/51)	Adults (18 to 60 years); MDD; acute suicidality excluded	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 1 year **TR+FU for analysis**: 1 year **FU used in analysis:** 1 year 1-year FU reported in Price (2023)	IV Ketamine (0.5 mg/kg), single dose Group 1: + Automated Self-Association Training (ASAT). Group 2: + sham ASAT	Placebo: saline + ASAT	MADRS-SI; QIDS-SR, data provided by author including data for 1-year FU (Price 2023)	Yes, directly No events in AE reported in trial register and confirmed by author	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
Rodriguez 2013 [104], USA, NCT01100255	15 (8/7)	Adults (18 to 55 years) with OCD, excluded when "prominent suicide ideation"	Double blind crossover RCT	**TR:** 24 hours (single dose), crossover after min. 7 days **TR+FU:** min. 14 days **TR+FU used for analysis:** 7 days	Intravenous ketamine (0.5 mg/kg), single dose	Placebo: saline	HDRS-SI, data unavailable	Yes, indirectly No events in AE reported in publication and on trial register	Yes
Schiweck 2021 [105], Belgium, EudraCT 2016-001715-21	28 (7/21) according to information on trial register	Adults (18 to 65 years) with MDD	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 4 days (6 days for responders, protocol and supplement says day 21) **TR+FU for analysis:** 4 days	Intravenous ketamine (0.5 mg/kg), single dose	Placebo: saline	HDRS-SI, data unavailable	Yes, indirectly No events in AE reported in trial register	Yes
Seraj 2025 [106], India, none reported	80 (40/40)	Adults (18 to 60 years) with MDD with suicide ideation	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 7 days **TR+FU for analysis:** 7 days	Oral ketamine (3mg/kg), single dose	Active control: Midazolam	Modified Scale for Suicide Ideation	Yes, directly No events reported in AE in publication	No
Shelton 2025 [107], USA and Spain, NCT03756129	70 (11/20 and 11/10/10/9 onfasprodil in different doses)	Adults (18-65 years) with MDD, no severe suicide ideation/risk	Double blind RCT	**TR:** 6 weeks **TR+FU:** 9 weeks **TR+FU for analysis:** 9 weeks	Intravenous ketamine, weekly for 6 weeks (0.5mg/kg)	Placebo	MADRS-SI data unavailable	Yes, directly No events in AE reported in trial register	Yes
Shiroma 2020 [108], USA, NCT02360280	58 (28/30)	Adults (18 to 75 years) with treatment resistant MDD, excluded when imminent risk of suicide ideation and/or behaviour with intent	Double blind RCT	**TR:** 10 days **TR+FU:** 6 months **TR+FU for analysis:** only 10-day TR can be used because afterwards both groups received ketamine	Intravenous ketamine (0.5mg/kg), thrice weekly	Active control: Midazolam	C-SSRS, data unavailable	Yes, indirectly No events in AE reported in trial register	No
Silberbauer 2025 [109], Austria, NCT02992496		Mean age ca. 40 (range not given) with MMD (including bipolar), suicidality not mentioned	Double blind RCT	**TR:** 11 days **TR+FU:** 11 days (no FU) **TR+FU for analysis:** 11 days	Oral ketamine (1mg/kg), 6 doses over 2 weeks	Active control: Midazolam	MADRS-SI data from authors	No Only specific AEs reported, no information on the trial register, no response from author	Yes
Singh 2016a [110], USA, NCT01627782	68 (35/33) Twice weekly:	Adults (18 to 64 years); MDD; excluded clinically	Double blind RCT with open label	**TR:** 4 weeks **TR+FU:** up to 13 weeks (optional open label phase after TR)	Intravenous ketamine (0.5 mg/kg) two or three times weekly for	Placebo: Sodium Chloride	C-SSRS, data via YODA	Yes, directly	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
	35 (18/17) Thrice weekly: 33 (17/16)	significant suicidal ideation	phase	**TR+FU for analysis: only** 15 days of TR, afterwards non-responders could leave study and open label phase was optional	4 weeks				
Singh 2016b [111], Europe, NCT01640080	30 (20/10)	Adults (18 to 64 years); MDD: excluded acutely suicidal	Double blind, double randomisation, RCT	**TR:** 1 week **TR+FU:** 5 weeks **TR+FU for analysis:** day 4 of TR, afterwards placebo non-responders received esketamine	IV Esketamine (2 groups: 0.20 mg/kg or 0.40 mg/kg), 2 doses over 4 days	Placebo	C-SSRS, data via YODA	Yes, directly	Yes
Smith-Apeldoorn 2024 [112], Netherlands NTR6161	113 (57/56)	Adults (18 to 80 years); MDD; excluded active suicidal intent	Double blind RCT followed by open label phase	**TR:** 6 weeks **TR+FU**: 16 weeks **TR+FU used for analysis:** 10 weeks (TR + 4-week washout phase but not 6 week open label phase)	Esketamine (30-90 mg/day) for 6 weeks	Placebo	HDRS-SI, data obtained from authors	Yes, directly	Yes
Sos 2013 [113], Czech Republic, EudraCT Nr. 2009-010625-39	30 (11/19) (pre-cross-over)	Adults (18 to 65 years); MDD; excluded any suicidal risk	Double blind cross-over RCT	**TR:** 24 hours (single dose), cross-over at day 7 **TR+FU:** 2 weeks **TR+FU for analysis:** 7 days – pre-cross-over period	IV Ketamine (0.27 mg/kg), single dose	Placebo: saline	MADRS-SI, data from Witt et al. 2019 who obtained data from authors	Yes, indirectly No events in AE reported in publication	No
Su 2017 [114], Taiwan, UMIN000016985	71 (47/24)	Adults, MDD; suicidality – not specified	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU:** 28 days **TR+FU for analysis:** 28 days	IV Ketamine, 2 groups: 0.2 or 0.5 mg/kg, single dose	Placebo: saline	HDRS-SI, data from Witt et al. (2019) who obtained data from author	Yes, indirectly No events in AE reported in publication	Yes
Su 2023 [115], Taiwan UMIN000033916 and UMIN000033760	84 (42/42)	Adults (20 to 64 years); MDD; included suicidal ideation	Double blind RCT	**Length of treatment phase:** 24 hours (single dose) **End of treatment FU**: 14 days **Total trial duration**: 14 days **FU used in analysis:** 14 days	IV Ketamine (0.5 mg/kg), single dose	Active control: Midazolam	C-SSRS, M's from figure, SD's imputed with the mean SD of other studies	Yes, directly (Note: suicide attempts reported but not in the study publication)	No
Sumner 2020 [37], New Zealand, ACTRN12615000573550	30 (17/16)	Adults; MDD; imminent risk of suicide excluded	Double blind cross-over RCT	**TR:** 24 hours (single dose), washout period min 3 weeks (4 weeks for women) then crossover **TR+FU:** min. 5 weeks **TR+FU for analysis:** 3 weeks	IV Ketamine (0.44 mg/kg), single dose	Active placebo: remifentanil	MADRS-SI, data provided by author	Yes, directly No information in publication but author confirmed that no events occurred.	No
Takahashi 2021, [116], Japan,	202 (122/80)	Adults (20 to 64 years); MDD;	Double blind RCT with	**TR:** 4 weeks **TR+FU:** 8-28 weeks	Esketamine nasal spray, 3 groups: 28, 56	Placebo	C-SSRS, data via YODA	Yes, directly	Yes

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
NCT02918318		excluded suicidal ideation with intent to act or suicidal behaviour	open label phase	**TR+FU for analysis:** only 4-week TR, afterwards open-label treatment for responders	or 84mg twice weekly for 4 weeks				
Taylor 2018 [117], USA, NCT02083926	18 (9/9)	Adults, Social anxiety disorder; suicidality – not specified	Double blind crossover RCT	**TR:** 24 hours (single dose), 28 day washout then crossover **TR+FU:** 42 days **TR+FU for analysis:** 28 days	IV Ketamine (0.5 mg/kg), single dose	Placebo: saline	HDRS-SI, data unavailable	Yes, indirectly No events in AE reported in trial register	Yes
Tiger 2020 [118], Sweden, none reported	30 (20/10)	Adults (20 to 80 years); MDD; excluded suicidality	Double blind RCT with open label phase	**TR:** 24 hours (single dose), open label phase **TR+FU:** 72 hours **TR+FU for analysis:** only 24-hour TR because afterwards all patients were treated open label	Ketamine (0.5 mg/kg) single dose	Placebo: saline	MADRS-SI, data unavailable	Yes, directly. Not reported but author confirmed that no events occurred.	No
Xiao 2023 [119], China ChiCTR2100050335	30 (15/15)	Adults (18 to 60 years); MDD; excluded suicidality	Double blind RCT	**TR:** 24 hours (single dose) **TR+FU**: 6 weeks **TR+FU for analysis:** 6 weeks	IV Esketamine (0.2 mg/kg), single dose	Active control: Midazolam	MADRS-SI, data unavailable	Yes, indirectly No events in AE reported in publication	No
Yoon 2025 [120], USA, NCT02461927	65 (21/22 and 22 to other arm not used for this analysis)	Adults (21-65 years), MDD and alcohol abuse symptoms, no imminent suicide risk	Double blind RCT	**TR:** 3 weeks **TR+FU:** 4 weeks **TR+FU for analysis:** 4 weeks	IV Ketamine (0.5mg/kg) plus saline, weekly for 4 weeks (the ketamine+naltextrone arms were not used here)	Active control: Midazolam	MADRS-SI data unavailable	Yes, directly No events in AE reported in publication and trial register	Yes
Zarate 2006 [121], USA, NCT00088699	18 (9/9)	Adults (18 to 65 years) with treatment resistant MDD without serious suicide risk	Doube blind crossover RCT	**TR:** 24 hours (single dose), crossover after 7 days **TR+FU**: 14 days **TR+FU for analysis:** 7 days, pre-cross-over	Ketamine (0.5 mg/kg) single dose	Placebo: saline	HDRS-SI, data provided by author	Yes, directly No events occurred as confirmed by authors	No
Zarate 2012 [122], USA, NCT00088699	Publication: 15 Full data-set: 44 (21/23)	Adults (18 to 65 years); Bipolar Affective Disorder; suicidality – not specified	Double blind cross-over RCT	**TR:** 24 hours (single dose), cross-over after 2 weeks **TR+FU:** 4 weeks **TR+FU for analysis:** 14 days, pre-cross over	IV Ketamine (0.5 mg/kg), single dose	Placebo: saline	MADRS-SI, data provided by author for full sample	Yes, directly No events in AE reported in trial register, confirmed by author	Yes
Zhou 2024 [123], China,	54 (27/27)	Adolescents (13 to 18 years); MDD;	Double blind RCT	**TR:** 6 days **TR+FU**: 33 days	IV Esketamine (0.25 mg/kg), 3 times over 5	Active control:	C-SSRS, change from	Yes, directly One event ("suicidal	No

Study, country, registration number	Total N randomised (intervention/control)	Sample (population, diagnosis; suicidality present)	Randomised Controlled Trial (RCT) design	Lengths of Treatment Phase (TR), TR+Follow-up Phase (TR+FU), and TR+FU used for analysis	Intervention, number of treatments, length of treatment	Control	Suicide ideation measures and data availability	Suicidal behaviour and deaths: information available (direct/indirect)?	Conflict of interest? Yes/No/not reported
ChiCTR2000041232		eligibility criteria included presence of suicidal ideation		**TR+FU for analysis:** 33 days	days	MIdazolam	baseline, n's from Fig. 2E, data for endpoints unavailable	behaviour") in Midazolam, assumed that this was a suicide attempt	

References are to be found in the online supplement.
AE: adverse events; BHS: Beck Hopelessness Scale; BDI-SI: suicide ideation item from the Beck Depression Inventory (BDI); BSS: Beck Scale for Suicide Ideation; C-SSRS: Columbia-Suicide Severity Rating Scale; CGI-SS-r: Clinical Global Impression of Severity of Suicidality Revised version; EPDS-SI: suicide ideation item from the Edinburgh Postpartal Depression Scale (EPDS); HDRS-SI: suicide idation item from the Hamilton Depression Rating Scale (HDRS); IN: intranasal; IV: Intravenous; M: mean; MADRS-SI: Montgomery- Åsberg Depression Rating Scale – suicidal ideation item; MDD: Major Depressive Disorder; QIDS-SR: Quick Inventory of Depressive Symptomatology – Self-Report; SD: standard deviation; SIBAT: Suicide Ideation and Behaviour Assessment Tool; SPS: Suicide Probability Scale; SSF: Suicide Status Form; SSI: Scale for Suicidal Ideation; SUD: substance use disorder; TRD: Treatment Resistant Depression; n: sample size; YODA: Yale University Open Data Access Project

In most trials, patients were continued on their antidepressant and we only reported other adjunct treatments.

a. Bittering agent simulates esketamine taste
b. Direct: suicidal events/deaths reported in publication or the trial register or via corresponding author; indirect: AE reported but no suicidal events/deaths seem to have occurred

Table 2: Summary of findings table with GRADE ratings.

Ketamine/esketamine compared to placebo (alone or with other treatments) for reducing suicide ideation/behaviour

Patient or population: reducing suicide ideation/behavior
Setting: Psychiatric Patients
Intervention: ketamine/esketamine
Comparison: placebo (alone or with other treatments)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with placebo (alone or with other treatments)	**Risk with ketamine/esketamine**				
Suicide ideation from 4 hours up to 24 hours	-	SMD **0.31 SD lower** (0.45 lower to 0.18 lower)	-	2073 (27 RCTs)	⊕⊕◯◯ Low[a,b]	The evidence suggests that ketamine/esketamine reduces suicide ideation within the first 24 hours
Suicide ideation from 24 hours up to 3 days	-	SMD **0.19 SD lower** (0.31 lower to 0.07 lower)	-	3139 (32 RCTs)	⊕⊕◯◯ Low[a,c]	The evidence suggests ketamine (but not esketamine) reduces suicide ideation from 24 hours up to 3 days.
Suicide ideation from 3 days up to 2 weeks	-	SMD **0.17 SD lower** (0.27 lower to 0.08 lower)	-	3496 (41 RCTs)	⊕⊕⊕◯ Moderate[a]	The evidence suggests that ketamine/esketamine results in little to no reduction in suicide ideation from 3 days up to 2 weeks.
Suicide ideation from 2 weeks up to 4 weeks	-	SMD **0.14 SD lower** (0.26 lower to 0.02 lower)	-	2795 (23 RCTs)	⊕⊕⊕◯ Moderate[a]	The evidence suggests that ketamine/esketamine results in little to no reduction in suicide ideation from 2 weeks up to 4 weeks.
Suicide ideation > 4 weeks	-	SMD **0.01 SD lower** (0.17 lower to 0.19 higher)	-	857 (11 RCTs)	⊕⊕⊕◯ Moderate[a]	Ketamine/esketamine likely results in little to no difference in suicide ideation > 4 weeks.
Suicide attempts and suicides combined	17 per 1.000	**17 per 1.000** (27 to 10)	**OR 0.98** (0.58 to 1.60)	5440 (72 RCTs)	⊕◯◯◯ Very low[a,d]	The evidence is very uncertain about the effect of ketamine/esketamine on suicide attempts and suicides combined.
Suicides	1 per 1.000	**1 per 1.000** (4 to 0)	**OR 1.58** (0.55 to 4.96)	5440 (72 RCTs)	⊕⊕◯◯ Low[a,d]	The evidence is very uncertain about the effect of ketamine/esketamine on Suicides.

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **OR:** odds ratio; **SMD:** standardised mean difference

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

a. The majority of trials is biased due to functional unblinding
b. Confidence intervals span into the range of clinical unimportance which we defined with as SMD < 0.3 (lower threshold) and SMD < 0.5 (conventional threshold)
c. Test of heterogeneity (tau) is statistically significant. However, heterogeneity is likely explained by the lack of efficacy for esketamine at this time-point.
d. Confidence/credible intervals are compatible with a protective and harmful effect extending into clinical meaningful ranges which we defined as OR <> 0 (liberal criterion) and 0.8 < OR < 1.2 (conservative criterion). Furthermore, the sample size is far less than the optimal information size.

Table 3: Meta-analysis of suicides and suicide attempts (Treatment + Follow-Up Phases combined)

Analysis	OR [95% CI]	p	I^2 [95% CI]	τ^2 [95%CI]	number of studies
Bayesian - Weak prior (1/250 < OR < 250)*	0.98 [0.58 - 1.60]			1.31 [1.01 - 2.49]	72
Bayesian - Informative prior (1/15 < OR < 15)	0.97 [0.58 - 1.58]			1.31 [1.01 - 2.50]	72
Exact (Liu et al. 2012)	1.06 [0.63 - 1.78]				72
Binomial-normal GLMM, fixed intercept	1.01 [0.65, 1.57]			0.00	
Binomial-normal GLMM, fixed intercept, alternative parameterization	1.01 [0.64, 1.57]			0.00	
Binomial-normal GLMM, random intercept	1.00 [0.64, 1.55]			0.00	
Binomial-normal GLMM, random intercept, alternative parameterization	1.00 [0.67, 1.55]			0.00	
Hypergeometric-normal GLMM (Nchg)	1.01 [0.67, 1.53]			0.00	
Conditional binomial GLMM (Condbin)	1.01 [0.32, 1.53]			0.00	
Beta-binomial model	0.75 [0.65, 1.73]				
Peto	1.01 [0.65 - 1.57]	0.96	25 [0 - 59]	0.00 [0.00 - 1.95]	16
Mantel-Haenszel - with continuity correction	0.92 [0.65 - 1.30]	0.64	0 [0 - 28]	0.00 [0.00 - 0.00]	72
Mantel-Haenszel - with continuity/treatment arm correction	1.00 [0.71 - 1.42]	0.98	0 [0 - 28]	0.00 [0.00 - 0.00]	72
Mantel-Haenszel - risk difference	0.00 [0.00 - 0.01]	0.59	0 [0 - 28]	0.00 [0.00 - 0.00]	72
Arcsine square root transformed risk difference	0.01 [-0.02 - 0.03]	0.63	0 [-]	0.00 [-]	72

Note: OR: odds-ratio, CI: confidence interval or credible interval for Bayesian analysis, p: p-value of odds-ratio, I^2 and τ^2: measures of heterogeneity, GLMM: generalized linear mixed models.
All methods are appropriate except Peto's method, because there are both single-arm-zero-events studies and double-arm-zero-events studies and the total event count in each arm is non-zero [29].
*Prioritized analysis, other methods should be considered as sensitivity analysis (see methods section).

Table 4: Meta-analysis of suicidal ideation

Result	up to 4h	>12h up to 24h	>24h up to 72h	>72h up to 2w	>2w up to 4w	>4w	End of Treatment
SMD [95%-CI]	-0.39 [-0.62 to -0.16]	-0.31 [-0.45 to -0.18]	-0.19 [-0.31 to -0.07]	-0.17 [-0.27 to -0.08]	-0.14 [-0.26 to -0.02]	0.01 [-0.17 to 0.19]	-0.25 [-0.35 to -0.15]
p	< 0.001	< 0.001	< 0.01	< 0.001	0.02	0.90	< 0.001
Heterogeneity	I2=58%, T2=0.23, p<0.001	I2=26%, T2=0.05, p=0.10	I2=41%, T2=0.06, p<0.01	I2=0%, T2=0.03, p=0.74	I2=12%, T2=0.03, p=0.29	I2=13%, T2=0.03, p=0.32	I2=25%, T2=0.05, p=0.07
Number of trials	26	27	32	41	23	11	44
Number of observations	1509	2073	3139	3496	2795	857	3582
Small study effect p-Value of Egger's regresson test	0.43	0.06	0.04	0.30	0.51	0.91	< 0.01

Note: SMD: standardized mean difference, CI: confidence interval, I^2 and τ^2: measures of heterogeneity, p: p-value

Table 5: Meta Analytic Results, Suicide Ideation - Subgroup Analyses

Subgroup analysis	**up to 4h**	**>12h up to 24h**	**>24h up to 72h**	**>72h up to 2w**	**>2w up to 4w**	**>4w**	**End of Treatment**
PRE-PLANNED							
Drug							
---Esketamine	-0.35 [-0.54 to -0.16]*	-0.16 [-0.32 to -0.01]*	-0.03 [-0.13 to 0.08]	-0.10 [-0.20 to 0.00]	-0.07 [-0.17 to 0.03]	0.04 [-0.27 to 0.35]	-0.07 [-0.17 to 0.03]
---Ketamine	-0.40 [-0.68 to -0.12]*	-0.39 [-0.57 to -0.20]*	-0.37 [-0.57 to -0.18]*	-0.25 [-0.40 to -0.10]*	-0.29 [-0.53 to -0.04]*	-0.02 [-0.26 to 0.22]	-0.43 [-0.57 to -0.29]*
--- test of difference (p-value)	0.10	< 0.01	< 0.001	0.02	< 0.01	0.55	< 0.001
Suicidality excl/incl criterion							
---Exclusion criterion or unknown	-0.20 [-0.59 to 0.20]	-0.20 [-0.40 to 0.00]	-0.06 [-0.18 to 0.06]	-0.14 [-0.25 to -0.02]*	-0.12 [-0.28 to 0.03]	0.13 [-0.13 to 0.38]	-0.16 [-0.28 to -0.04]*
---Inclusion criterion	-0.48 [-0.76 to -0.21]*	-0.39 [-0.58 to -0.21]*	-0.38 [-0.60 to -0.15]*	-0.25 [-0.42 to -0.07]*	-0.17 [-0.36 to 0.01]	-0.09 [-0.32 to 0.13]	-0.38 [-0.56 to -0.21]*
--- test of difference (p-value)	0.11	0.02	< 0.001	0.08	0.24	0.12	< 0.001
Rating							
---Clinician	no study	-0.30 [-0.44 to -0.15]*	no study	no study	-0.15 [-0.28 to -0.03]*	-0.05 [-0.25 to 0.16]	no study
---Patient	in one subgroup	-0.47 [-0.94 to -0.01]*	in one subgroup	in one subgroup	0.05 [-0.45 to 0.56]	-0.01 [-0.41 to 0.40]	in one subgroup
--- test of difference (p-value)		0.26			0.43	0.86	
Placebo							
---Active	-0.27 [-0.62 to 0.09]	-0.40 [-0.63 to -0.18]*	-0.36 [-0.61 to -0.10]*	-0.26 [-0.50 to -0.03]*	-0.16 [-0.47 to 0.16]	0.02 [-0.36 to 0.40]	-0.46 [-0.65 to -0.27]*
---Non-active	-0.48 [-0.77 to -0.19]*	-0.25 [-0.43 to -0.08]*	-0.13 [-0.27 to 0.00]	-0.15 [-0.24 to -0.05]*	-0.14 [-0.26 to -0.01]*	0.01 [-0.19 to 0.21]	-0.16 [-0.27 to -0.05]*
--- test of difference (p-value)	0.89	0.04	< 0.01	0.14	0.67	0.93	< 0.001
EXPLORATIVE							

Doses							
---Repeated				-0.14 [-0.25 to -0.04]*	-0.12 [-0.22 to -0.01]*	0.01 [-0.20 to 0.22]	
---Single				-0.24 [-0.44 to -0.04]*	-0.17 [-0.57 to 0.22]	0.02 [-0.40 to 0.44]	
--- test of difference (p-value)				0.12	0.16	0.96	

Note: Results are standardized mean differences with their 95%-confidence intervals in brackets
* $p < 0.05$

REFERENCES

1 World Health Organization. *Suicide in the world. Global health estimates.* World Health Organization 2019.

2 UK Parliament. Suicide Statistics. UK: House of Commons Library 2025.

3 Ilic M, Ilic I. Worldwide suicide mortality trends (2000-2019): A joinpoint regression analysis. *World J Psychiatry*. 2022;12:1044–60. doi: 10.5498/wjp.v12.i8.1044

4 Xu YE, Barron DA, Sudol K, *et al.* Suicidal behavior across a broad range of psychiatric disorders. *Mol Psychiatry*. 2023;28:2764–810. doi: 10.1038/s41380-022-01935-7

5 Price RB, Mathew SJ. Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions. *CNS Drugs*. 2015;29:181–8. doi: 10.1007/s40263-015-0232-4

6 Johns Hopkins Medicine. Esketamine for Treatment-Resistant Depression. 2023. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/esketamine-for-treatment-resistant-depression (accessed 2 April 2025)

7 Johnson & Johnson. SPRAVATO® (esketamine). Official Patient Website. https://www.spravato.com/what-is-spravato/ (accessed 2 April 2025)

8 Hochschild A, Grunebaum MF, Mann JJ. The rapid anti-suicidal ideation effect of ketamine: A systematic review. *Preventive Medicine*. 2021;152:106524. doi: 10.1016/j.ypmed.2021.106524

9 McIntyre RS, Rosenblat JD, Nemeroff CB, *et al.* Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. *Am J Psychiatry*. 2021;appiajp202020081251. doi: 10.1176/appi.ajp.2020.20081251

10 Ng J, Rosenblat JD, Lui LMW, *et al.* Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. *Journal of Affective Disorders*. 2021;293:285–94. doi: 10.1016/j.jad.2021.06.032

11 Walsh Z, Mollaahmetoglu OM, Rootman J, *et al.* Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. *BJPsych Open*. 2022;8:e19. doi: 10.1192/bjo.2021.1061

12 Gastaldon C, Raschi E, Kane JM, *et al.* Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. *Psychother Psychosom*. 2020;1–8. doi: 10.1159/000510703

13 Chang H, Huang M-C, Chen L-Y. Major Depressive Disorder Induced by Chronic Ketamine Abuse: A Case Report. *Prim Care Companion CNS Disord*. Published Online First: 23 June 2016. doi: 10.4088/PCC.15l01881

14 Liang HJ, Tang KL, Chan F, *et al.* Ketamine Users Have High Rates of Psychosis and/or Depression. *Journal of Addictions Nursing*. 2015;26:8–13. doi: 10.1097/JAN.0000000000000060

15 Morgan CJA, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. *Addiction*. 2009;104:77–87. doi: 10.1111/j.1360-0443.2008.02394.x

16 Alario AA, Niciu MJ. (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy. *Chronic Stress*. 2022;6:24705470221128016. doi: 10.1177/24705470221128017

17 Shamabadi A, Ahmadzade A, Hasanzadeh A. Ketamine for suicidality: An umbrella review. *Brit J Clinical Pharma*. 2022;88:3990–4018. doi: 10.1111/bcp.15360

18 Witt K, Potts J, Hubers A, *et al.* Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. *Aust N Z J Psychiatry*. 2020;54:29–45. doi: 10.1177/0004867419883341

19 Jollant F, Colle R, Nguyen TML, *et al.* Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review. *Therapeutic Advances in Psychopharmacology*. 2023;13:204512532311513. doi: 10.1177/20451253231151327

20 Juul S, Faltermeier P, Siddiqui F, *et al.* Challenges in the selection and measurement of outcomes in psychiatric trials. *BMJ EBM*. 2025;bmjebm-2024-113171. doi: 10.1136/bmjebm-2024-113171

21 Xu C, Furuya-Kanamori L, Islam N, *et al.* Should studies with no events in both arms be excluded in evidence synthesis? *Contemporary Clinical Trials*. 2022;122:106962. doi: 10.1016/j.cct.2022.106962

22 Liu D, Liu RY, Xie M. Exact Meta-Analysis Approach for Discrete Data and its Application to 2 × 2 Tables With Rare Events. *Journal of the American Statistical Association*. 2014;109:1450–65. doi: 10.1080/01621459.2014.946318

23 Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. *AJP*. 2025;182:259–75. doi: 10.1176/appi.ajp.20240515

24 Chen C-C, Zhou N, Hu N, *et al.* Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis. *NDT*. 2023;Volume 19:587–99. doi: 10.2147/ndt.s401032

25 Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;n71. doi: 10.1136/bmj.n71

26 Higgins JPT, Altman DG, Gotzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928–d5928. doi: 10.1136/bmj.d5928

27 Zeng L, Brignardello-Petersen R, Hultcrantz M, *et al.* GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *Journal of Clinical Epidemiology*. 2022;150:216–24. doi: 10.1016/j.jclinepi.2022.07.014

28 Neumann I, Schünemann H. The GRADE Book version 1.0 (updated September 2024). The GRADE Working Group. 2024. https://book.gradepro.org (accessed 20 December 2025)

29 Xu C, Furuya-Kanamori L, Zorzela L, *et al.* A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. *Journal of Clinical Epidemiology*. 2021;135:70–8. doi: 10.1016/j.jclinepi.2021.02.012

30 Plöderl M, Hengartner MP, Bschor T, *et al.* Commentary to 'antidepressants and suicidality: A re-analysis of the re-analysis'. *J Affect Disord*. 2020;273:252–3. doi: 10.1016/j.jad.2020.04.025

31 Günhan BK, Röver C, Friede T. Random-effects meta-analysis of few studies involving rare events. *Research Synthesis Methods*. 2020;11:74–90. doi: 10.1002/jrsm.1370

32 Jansen K, Holling H. Random-effects meta-analysis models for the odds ratio in the case of rare events under different data-generating models: A simulation study. *Biometrical J*. 2023;65:2200132. doi: 10.1002/bimj.202200132

33 Higgins JPT, Thomas CJ, Chandler J, *et al.* Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane 2024.

34 Wan X, Wang W, Liu J, *et al.* Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14:135. doi: 10.1186/1471-2288-14-135

35 Burger J, Capobianco M, Lovern R, *et al.* A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting. *Mil Med*. 2016;181:1195–9.

36 R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing 2025.

37 Sumner R.L., McMillan R., Spriggs M.J., *et al.* Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2020;5:45–55. doi: 10.1016/j.bpsc.2019.07.002

38 Fava M, Freeman MP, Flynn M, *et al.* Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Molecular Psychiatry*. 2020;25:1592–603. doi: 10.1038/s41380-018-0256-5

39 Anderson IM, Blamire A, Branton T, *et al.* Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. *The lancet Psychiatry*. 2017;4:365. doi: 10.1016/S2215-0366(17)30077-9

40 Lii TR, Smith AE, Flohr JR, *et al.* Randomized trial of ketamine masked by surgical anesthesia in patients with depression. *Nat Mental Health*. 2023;1:876–86. doi: 10.1038/s44220-023-00140-x

41 Dwyer J.B., Landeros-Weisenberger A., Johnson J.A., *et al.* Efficacy of intravenous ketamine in adolescent treatment-resistant depression: A randomized midazolam-controlled trial. *Am J Psychiatry*. 2021;178:352–62. doi: 10.1176/appi.ajp.2020.20010018

42 Fineberg SK, Choi EY, Shapiro-Thompson R, *et al.* A pilot randomized controlled trial of

ketamine in Borderline Personality Disorder. *Neuropsychopharmacology*. 2023;48:991–9. doi: 10.1038/s41386-023-01540-4

43 Glue P, Neehoff S, Beaglehole B, *et al.* Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. *J Psychopharmacol*. 2024;38:162–7. doi: 10.1177/02698811241227026

44 Järventausta K, Chrapek W, Kampman O, *et al.* Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. *Journal of ECT*. 2013;29:158. doi: 10.1097/YCT.0b013e318283b7e9

45 Chen Q, Min S, Hao X, *et al.* Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy-A Randomized, Double-Blind, Controlled Clinical Study. *J ECT*. 2017;33:89–95. doi: 10.1097/YCT.0000000000000365

46 Loo C.K., Katalinic N., Garfield J.B.B., *et al.* Neuropsychological and mood effects of ketamine in electroconvulsive therapy: A randomised controlled trial. *J Affective Disord*. 2012;142:233–40. doi: 10.1016/j.jad.2012.04.032

47 Woolsey A.J., Nanji J.A., Moreau C., *et al.* Low-dose ketamine does not improve the speed of recovery from depression in electroconvulsive therapy: A randomized controlled trial. *Brazilian Journal of Psychiatry*. 2022;44:6–14. doi: 10.1590/1516-4446-2020-1705

48 Kaliora S., Braga R., Hirapara K., *et al.* Does ketamine anesthesia during electroconvulsive therapy offer efficacy advantages over standard methohexital anesthesia? a randomized pilot study. *Neuropsychopharmacology*. 2017;43:S385–6. doi: 10.1038/npp.2017.265

49 Ray-Griffith SL, Eads LA, Han X, *et al.* A randomized pilot study comparing ketamine and methohexital anesthesia for electroconvulsive therapy in patients with depression. *The Journal of ECT*. 2017;33:268–71. doi: 10.1097/YCT.0000000000000413

50 Jelovac A., McCaffrey C., Terao M., *et al.* Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial. *JAMA Psychiatry*. Published Online First: 2025. doi: 10.1001/jamapsychiatry.2025.3019

51 Sharma T, Guski LS, Freund N, *et al.* Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ*. Published Online First: 27 January 2016. doi: 10.1136/bmj.i65

52 Le Noury J, Nardo JM, Healy D, *et al.* Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. *BMJ*. 2015;h4320. doi: 10.1136/bmj.h4320

53 Witt K, Townsend E, Arensman E, *et al.* Psychosocial Interventions for People Who Self-Harm: Methodological Issues Involved in Trials to Evaluate Effectiveness. *Archives of Suicide Research*. 2020;24:S32–93. doi: 10.1080/13811118.2019.1592043

54 Abbar M, Demattei C, El-Hage W, *et al.* Ketamine for the acute treatment of severe suicidal ideation: Double blind, randomised placebo controlled trial. *BMJ: British Medical Journal*.

2022;376.

55 Nikolin S, Rodgers A, Schwaab A, *et al.* Ketamine for the treatment of major depression: a systematic review and meta-analysis. *eClinicalMedicine*. 2023;62:102127. doi: 10.1016/j.eclinm.2023.102127

56 Feng W, Chen C, Zeng Y, *et al.* Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: A meta-analysis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2025;136:111152. doi: 10.1016/j.pnpbp.2024.111152

57 Glue P, Loo C, Fam J, *et al.* Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. *Nat Med*. 2024;30:2004–9. doi: 10.1038/s41591-024-03063-x

58 Daly E.J., Trivedi M.H., Janik A., *et al.* Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial. *JAMA Psychiatry*. 2019;76:893–903. doi: 10.1001/jamapsychiatry.2019.1189

59 Morgan CJA, Curran HV, the Independent Scientific Committee on Drugs (ISCD). Ketamine use: a review. *Addiction*. 2012;107:27–38. doi: 10.1111/j.1360-0443.2011.03576.x

60 Liu Y, Lin D, Wu B, *et al.* Ketamine abuse potential and use disorder. *Brain Research Bulletin*. 2016;126:68–73. doi: 10.1016/j.brainresbull.2016.05.016

61 Abdallah C.G., Roache J.D., Gueorguieva R., *et al.* Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. *Neuropsychopharmacology*. 2022;47:1574–81. doi: 10.1038/s41386-022-01266-9

62 Ahmed GK, Elserogy YM, Elfadl GMA, *et al.* Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. *J Affect Disord*. 2023;325:127–34. doi: 10.1016/j.jad.2023.01.005

63 Anderson IM, Blamire A, Branton T, *et al.* Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study). *Efficacy Mech Eval*. 2017;4:1–112. doi: 10.3310/eme04020

64 Barzkar M, Alavi K, Malakouti K, *et al.* Is ketamine efficacious for rapid treatment of acute suicidal ideation in an emergency setting? Lessons learned from a pilot randomized controlled trial. *BMC Res Notes*. 2025;18:65. doi: 10.1186/s13104-024-07029-7

65 Canuso C.M., Singh J.B., Fedgchin M., *et al.* Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*. 2018;175:620–30. doi: 10.1176/appi.ajp.2018.17060720

66 Chen X, Hou X, Bai D, *et al.* Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. *NDT*. 2023;Volume 19:693–707. doi: 10.2147/NDT.S391096

67 Colla M, Offenhammer B, Scheerer H, *et al.* Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results. *J Psychiatr Res*. 2024;173:124–30. doi: 10.1016/j.jpsychires.2024.03.002

68 Dakwar E., Nunes E.V., Hart C.L., *et al.* A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. *Am J Psychiatry*. 2019;176:923–30. doi: 10.1176/appi.ajp.2019.18101123

69 Dakwar E., Levin F., Hart C.L., *et al.* A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. *Am J Psychiatry*. 2020;177:125–33. doi: 10.1176/appi.ajp.2019.19070684

70 Daly E.J., Singh J.B., Fedgchin M., *et al.* Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. *JAMA Psychiatry*. 2018;75:139–48. doi: 10.1001/jamapsychiatry.2017.3739

71 Domany Y., Bleich-Cohen M., Tarrasch R., *et al.* Repeated oral ketamine for out-patient treatment of resistant depression: Randomised, double-blind, placebo-controlled, proof-of-concept study. *Br J Psychiatry*. 2019;214:20–6. doi: 10.1192/bjp.2018.196

72 Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. *Depression and anxiety*. 2020;37:224. doi: 10.1002/da.22975

73 Domany Y, McCullumsmith CB. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: a Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. *Archives of suicide research*. 2022;26:1250. doi: 10.1080/13811118.2021.1878078

74 Duek O, Korem N, Li Y, *et al.* Long term structural and functional neural changes following a single infusion of Ketamine in PTSD. *Neuropsychopharmacology*. 2023;48:1648–58. doi: 10.1038/s41386-023-01606-3

75 Feder A, Parides MK, Murrough JW, *et al.* Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. *JAMA psychiatry*. 2014;71:681. doi: 10.1001/jamapsychiatry.2014.62

76 Feder A, Costi S, Rutter SB, *et al.* A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. *American journal of psychiatry*. 2021;178:193. doi: 10.1176/appi.ajp.2020.20050596

77 Fedgchin M, Trivedi M, Daly EJ, *et al.* Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). *Int J*

Neuropsychopharmacol. 2019;22:616–30. doi: 10.1093/ijnp/pyz039

78 Gallagher B, Foley M, Slattery CM, *et al.* Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial). *HRB Open Res.* 2022;3:90. doi: 10.12688/hrbopenres.13182.2

79 George D, Gálvez V, Martin D, *et al.* Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. *American journal of geriatric psychiatry*. 2017;25:1199. doi: 10.1016/j.jagp.2017.06.007

80 Grabski M, McAndrew A, Lawn W, *et al.* Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. *Am J Psychiatry*. 2022;179:152–62. doi: 10.1176/appi.ajp.2021.21030277

81 Grunebaum MF, Ellis SP, Keilp JG, *et al.* Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. *Bipolar Disord*. 2017;19:176–83. doi: 10.1111/bdi.12487

82 Grunebaum MF, Galfalvy HC, Choo T-H, *et al.* Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. *Am J Psychiatry*. 2018;175:327–35. doi: 10.1176/appi.ajp.2017.17060647

83 Hong X, Xu S, Sun G, *et al.* Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial. *J Affect Disord*. 2025;383:1–10. doi: 10.1016/j.jad.2025.04.077

84 Hu Y.-D., Xiang Y.-T., Fang J.-X., *et al.* Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. *Psychol Med*. 2016;46:623–35. doi: 10.1017/S0033291715002159

85 Ionescu D.F., Bentley K.H., Eikermann M., *et al.* Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. *J Affective Disord*. 2019;243:516–24. doi: 10.1016/j.jad.2018.09.037

86 Ionescu DF, Fu DJ, Qiu X, *et al.* Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). *The international journal of neuropsychopharmacology*. 2021;24:22. doi: 10.1093/ijnp/pyaa068

87 Janik A., Qiu X., Lane R., *et al.* Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. *JAMA Psychiatry*. 2025;82:877–87. doi: 10.1001/jamapsychiatry.2025.1317

88 Jones GH, Vecera CM, Ruiz AC, *et al.* A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder. *J Clin Psychiatry*. 2024;85:23m14974. doi: 10.4088/JCP.23m14974

89 Kosik-Gonzalez C., Fu D.-J., Chen L.N., *et al.* Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized

Psychoactive-Controlled Study. *J Am Acad Child Adolesc Psychiatry*. Published Online First: 2025. doi: 10.1016/j.jaac.2025.02.015

90 Lapidus KAB, Levitch CF, Perez AM, *et al.* A randomized controlled trial of intranasal ketamine in major depressive disorder. *Biol Psychiatry*. 2014;76:970–6. doi: 10.1016/j.biopsych.2014.03.026

91 Leal GC, Souza-Marques B, Mello RP, *et al.* Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. *J Affect Disord*. 2023;330:7–15. doi: 10.1016/j.jad.2023.02.151

92 Lijffijt M, Murphy N, Iqbal S, *et al*. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. *Neuropsychopharmacology*. 2022;47:1088–95. doi: 10.1038/s41386-021-01242-9

93 Loo CK, Gálvez V, O'Keefe E, *et al.* Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. *Acta psychiatrica Scandinavica*. 2016;134:48. doi: 10.1111/acps.12572

94 Loo C, Glozier N, Barton D, *et al.* Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. *Br J Psychiatry*. 2023;223:533–41. doi: 10.1192/bjp.2023.79

95 Milak M.S., Rashid R., Dong Z., *et al.* Assessment of Relationship of Ketamine Dose with Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults with Major Depression: A Randomized Clinical Trial. *JAMA Netw Open*. 2020;3:e2013211. doi: 10.1001/jamanetworkopen.2020.13211

96 Murrough JW, Iosifescu DV, Chang LC, *et al.* Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. *Am J Psychiatry*. 2013;170:1134–42. doi: 10.1176/appi.ajp.2013.13030392

97 Murrough JW, Soleimani L, DeWilde KE, *et al.* Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. *Psychol Med*. 2015;45:3571–80. doi: 10.1017/S0033291715001506

98 Ochs-Ross R, Daly EJ, Zhang Y, *et al.* Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3. *Am J Geriatr Psychiatry*. 2020;28:121–41. doi: 10.1016/j.jagp.2019.10.008

99 Ohtani Y, Tani H, Nomoto-Takahashi K, *et al.* Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial. *Psychiatry Clin Neurosci*. 2024;78:765–75. doi: 10.1111/pcn.13734

100 Pattanaseri K, Lortrakul J, Jaisin K, *et al.* A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression. *BMC Psychiatry*. 2024;24:512. doi: 10.1186/s12888-024-05951-5

101 Phillips J.L., Norris S., Talbot J., *et al.* Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. *Am J Psychiatry*. 2019;176:401–9. doi: 10.1176/appi.ajp.2018.18070834

102 Popova V, Daly EJ, Trivedi M, *et al.* Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. *Am J Psychiatry*. 2019;176:428–38. doi: 10.1176/appi.ajp.2019.19020172

103 Price RB, Spotts C, Panny B, *et al.* A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. *Am J Psychiatry*. 2022;179:959–68. doi: 10.1176/appi.ajp.20220216

104 Rodriguez CI, Kegeles LS, Levinson A, *et al.* Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. *Neuropsychopharmacology*. 2013;38:2475. doi: 10.1038/npp.2013.150

105 Schiweck C., Lutin E., De Raedt W., *et al.* Twenty-Four-Hour Heart Rate Is a Trait but Not State Marker for Depression in a Pilot Randomized Controlled Trial With a Single Infusion of Ketamine. *Front Psychiatry*. 2021;12:696170. doi: 10.3389/fpsyt.2021.696170

106 Seraj A., Reyazuddin M., Gaur R.K., *et al.* Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial. *Asian J Psychiatry*. 2025;106:104413. doi: 10.1016/j.ajp.2025.104413

107 Shelton RC, Litman RE, Hassman H, *et al.* Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study. *J Clin Psychiatry*. 2025;86. doi: 10.4088/JCP.23m15246

108 Shiroma P.R., Thuras P., Wels J., *et al.* A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. *Transl Psychiatry*. 2020;10:206. doi: 10.1038/s41398-020-00897-0

109 Silberbauer LR, Eggerstorfer B, Michenthaler P, *et al.* Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis. *J Affect Disord*. 2026;394:120466. doi: 10.1016/j.jad.2025.120466

110 Singh J.B., Fedgchin M., Daly E.J., *et al.* A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. *Am J Psychiatry*. 2016;173:816–26. doi: 10.1176/appi.ajp.2016.16010037

111 Singh JB, Fedgchin M, Daly E, *et al.* Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. *Biol Psychiatry*. 2016;80:424–31. doi: 10.1016/j.biopsych.2015.10.018

112 Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, *et al.* Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. *Mol Psychiatry*. 2024;29:2657–65. doi: 10.1038/s41380-024-02478-9

113 Sos P, Klirova M, Novak T, *et al.* Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. *Neuroendocrinol Lett*. 2013;34:287–93.

114 Su T-P, Chen M-H, Li C-T, *et al.* Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. *Neuropsychopharmacol*. 2017;42:2482–92. doi: 10.1038/npp.2017.94

115 Su T-P, Li C-T, Lin W-C, *et al.* A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. *Int J Neuropsychopharmacol*. 2023;26:331–9. doi: 10.1093/ijnp/pyad014

116 Takahashi N, Yamada A, Shiraishi A, *et al.* Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. *BMC Psychiatry*. 2021;21:526. doi: 10.1186/s12888-021-03538-y

117 Taylor JH, Landeros-Weisenberger A, Coughlin C, *et al.* Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. *Neuropsychopharmacology*. 2018;43:325–33. doi: 10.1038/npp.2017.194

118 Tiger M, Veldman ER, Ekman CJ, *et al.* A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. *Translational psychiatry*. 2020;10:159. doi: 10.1038/s41398-020-0844-4

119 Xiao C, Zhou J, Li A, *et al.* Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial. *JAMA Netw Open*. 2023;6:e2328817. doi: 10.1001/jamanetworkopen.2023.28817

120 Yoon G, Pittman B, Ralevski E, *et al.* Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial. *Int J Neuropsychopharmcol*. 2025;28. doi: 10.1093/ijnp/pyaf056

121 Zarate CA, Singh JB, Carlson PJ, *et al.* A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of general psychiatry*. 2006;63:856. doi: 10.1001/archpsyc.63.8.856

122 Zarate CA, Brutsche NE, Ibrahim L, *et al.* Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biological psychiatry*. 2012;71:939. doi: 10.1016/j.biopsych.2011.12.010

123 Zhou Y, Lan X, Wang C, *et al.* Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial. *J Am Acad Child Adolesc Psychiatry*. 2024;63:507–18. doi: 10.1016/j.jaac.2023.05.031


Reduction of Suicide Ideation by Drug over Time
All
Esketamine
Ketamine
effect size
0.2
0.0
−0.2
−0.4
−0.6
up to 4h
>12h up to 24h
>24h up to 72h
>72h up to 2w
>2w up to 4w
>4w
time


Identification of new studies via databases and registers
Identification of new studies via other methods
Identification
Screening
Included
Records identified from:
Databases (n = 3,118)
Registers (n = 0)
Records removed before screening:
Duplicate records (n = 930)
Records marked as ineligible by automation tools (n = 0)
Records removed for other reasons (n = 0)
Records identified from:
Websites (n = 0)
Organisations (n = 0)
Citation searching (n = 15)
Records screened
(n = 2,188)
Records excluded
(n = 1,939)
Reports sought for retrieval
(n = 249)
Reports not retrieved
(n = 0)
Reports sought for retrieval
(n = 15)
Reports not retrieved
(n = 0)
Reports assessed for eligibility
(n = 249)
Reports excluded:
Study already included/secondary analysis (n = 97)
Excluded Study Design (n = 34)
Excluded study population (n = 20)
No data available (n = 24)
No relevant outcome (n = 3)
Reports assessed for eligibility
(n = 15)
Reports excluded:
Study already included/secondary analysis (n = 8)
Excluded Study Design (n = 4)
Excluded study population (n = 1)
New studies included in review
(n = 73)
Reports of new included studies
(n = 73)